• Explore /
  • Poster
  • / Feasibility of SM-88 in PC after multiple prior lines and ECOG < 2 (NCT03512756).

Feasibility of SM-88 in PC after multiple prior lines and ECOG < 2 (NCT03512756).

Abstract Poster

Authors

null

Marcus Smith Noel

University of Rochester James P. Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY

Marcus Smith Noel , Andrea Wang-Gillam , Allyson J. Ocean , Giuseppe Del Priore , Vincent J. Picozzi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT03512756

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 310)

DOI

10.1200/JCO.2019.37.4_suppl.310

Abstract #

310

Poster Bd #

G8

Abstract Disclosures

Similar Posters

First Author: Ciara Conduit

Poster

2023 ASCO Genitourinary Cancers Symposium

Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

First Author: Lisa M. Gudenkauf

First Author: Patrick Glen Pilié

First Author: David Tougeron